[Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody]

Abstract

Molecular signals of RANK/RANK/OPG, essentially required in osteoclast differentiation, have been shown to pertain to joint destruction in rheumatoid arthritis (RA) . In rodent adjuvant arthritis systemic administration of OPG did not prevent inflammation, but effectively reduced joint destruction preserving peri-arthritic bone mass. In clinical trial anti-RANKL antibody (Denosumab) injection once in every 6 months alleviated the worsening of joint erosion in hands for a year in patients with RA. Although RANKL/RANK signals have not been confirmed as the exclusive causative factor to joint destruction and bone loss, a new horizon may be brought about by Denosumab in the treatment of RA.